Evidence map›Paper›PMID 38110341›Full record

ArticleBMJ case reports2023

Denosumab for an inoperable giant cell tumour of the ischial bone.

Aaron Gerarde Paul, Lei Peng See, May Honey Ohn, Khin Maung Ohn

Open access · greenAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in BMJ case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Aaron Gerarde PaulOrthopaedic Surgery, Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia.
Lei Peng SeeOrthopaedic Surgery, Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia.
May Honey OhnCardiology, St George's University Hospitals NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-1951-6598
Khin Maung OhnOrthopaedic Surgery, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia drkmgohn@ums.edu.my.
Queen Elizabeth Hospital · MYSt George’s University Hospitals NHS Foundation Trust · GBUniversiti of Malaysia Sabah · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Giant cell tumour of bone is a benign, locally aggressive osteolytic tumour that typically affects skeletally mature young individuals. It predominantly emerges within the metaphysis, extending towards the epiphysis of long bones, while occurrences in flat bones are exceptionally rare. We present a case of a woman in her late 20s who presented with a large right ischial mass. A biopsy confirmed the mass as a giant cell tumour. The tumour extended to the acetabulum, and due to the potential risk of significant bleeding and contamination during en bloc excision, a prudent approach involved initiating denosumab therapy, a monoclonal antibody targeting receptor activator of nuclear factor-κB ligand therapy, before proceeding with radical surgery. Denosumab therapy successfully rendered a previously inoperable tumour favourable for surgical intervention. We went on to perform a type 2 and 3 internal hemipelvectomy, followed by a reconstruction with a hip endoprosthesis replacement.

Indexed as

Bone Density Conservation AgentsBone NeoplasmsGiant Cell Tumor of BoneSpinal NeoplasmsBiopsyDenosumabFemaleHumansBone Density Conservation AgentsDenosumabDrug therapy related to surgeryOrthopaedic and trauma surgerySurgical oncology

Identifiers

PMID38110341
OpenAlexW4389902286

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.